ButterflyBVM recall shows how device defects reach PV teams in the same week as drug-container leaks

What happened

On 3 November 2026 the FDA published an early alert on Compact Medical's ButterflyBVM resuscitator. The company is removing nine lots and applying a pre-use test correction to 22 others, after holes were found forming in the bellows.

The two actions are different. Removal means the nine lots are being taken out of the supply chain. A correction means the other 22 lots can stay in use, but users are expected to follow an added pre-use check. The FDA's early alert system is meant to communicate about device problems that may be high-risk while the situation is still developing, so the picture is likely to change.

The record does not say how the holes were detected. It also gives no distribution figures, no information on injuries or complaints, and no root cause. Those facts are not yet known from the material available, and nobody should infer harm or its absence from the notice.

Why a bellows defect matters

A bag-valve-mask is used to push air into a patient who is not breathing adequately. Holes in the bellows would be a fault in the part that moves the air. The pre-use test correction suggests the company wants users to catch a faulty unit before it is used on a patient. Whether that check is sufficient is a question for the FDA and the manufacturer, and the records do not address it.

For safety teams the practical point is detection. A defect that develops over time, as 'forming' suggests, is harder to catch at release than one present from manufacture. It also puts weight on how users report a unit that fails in the field. Emergency-use equipment often sits in kits and vehicles, so affected units may not be easy to locate.

A pattern across containers and devices

The ButterflyBVM alert is one of three leak or integrity cases in the 2–3 November records.

On 2 November the FDA published an early alert on B. Braun Streamline Bloodline Sets for Dialog+. B. Braun says a missed solvent step during assembly left the dialyzer connector inadequately bonded on three lots. The stated risks are leaks, blood loss and air entry during haemodialysis.

On 3 November Health Canada flagged manufacturing-related leak defects in certain lots of Fresenius Kabi Canada's sodium citrate 4g/100mL anticoagulant for apheresis. It advised bag-by-bag checks rather than withdrawal.

These cases differ in product type, jurisdiction and regulatory response. One is a recall-style removal with a correction, one a recall tied to a missed assembly step, and one a regulator-advised user check without recall. Together they show that a physical defect can lead to very different actions depending on the product and the agency. A drug in a bag is a medicine whose container has failed. A resuscitator is a device. A PV or quality team handling combination products or drug-device interfaces may receive both kinds of report through the same inbox.

Regulatory and PV context

Medicine-focused PV teams may not own device vigilance. But complaint handling, quality-defect reporting and adverse-event intake often overlap, particularly where a container or delivery system is involved. A leak report may be coded as a product quality complaint first and only later recognised as having a patient-safety dimension.

The timing also coincides with #MedSafetyWeek 2026, which runs 2–8 November. Portugal's INFARMED and Austria's BASG with AGES have joined the 11th campaign urging reporting of suspected side effects. BASG cited 14,528 Austrian pharmacovigilance reports for 2025 and noted a changed counting method. That caveat matters: year-on-year comparisons of report volumes need care when the counting basis has changed.

Two other items affect the PV workload. The EMA has published Appendix V of the QRD documentation, covering the standard statement and contact details for reporting suspected adverse reactions. The records do not say what changed, so teams should read the document against their current product-information text instead of assuming nothing has changed. Separately, PRAC has started an EU-wide review of the flupentixol/melitracen combination (Deanxit) after Belgium raised concerns about severe, long-lasting and possibly irreversible neurological and psychiatric side effects. The outcome of that review is not yet known.

What to watch

For the ButterflyBVM, the open questions are the cause of the holes, whether any adverse events have been linked to them, and whether the correction is extended or the removal widened. Watch the FDA page for updates.

For the sodium citrate bags, watch for any move from user-level checks to a withdrawal, and whether other markets act on the same lots. For Deanxit, watch the PRAC timetable and any interim communication to prescribers. For the QRD appendix, watch for guidance on timelines for implementing the updated wording.